BioSpace News Archive

Synthorx, Inc., a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced company researchers will present results of preclinical studies demonstrating the safety and anti-tumor effects of its lead product candidate THOR-707

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the third quarter ended September 30, 2018 and provided a corporate updat

Robotic exoskeleton manufacturer has provided life changing medical devices for persons with spinal cord injury in 26 countries

Phase 2 Data Presented on Investigational FXR Agonist GS-9674 in NASH

Calliditas Therapeutics AB (publ) today announced that management will present at the Stifel 2018 Healthcare Conference taking place November 13-14 at the Lotte New York Palace Hotel.

Addiction Treatment Company Celebrates 10th-Year as New Facility Opens

Medical publications are an important and credible means of communicating relevant scientific information about a pharmaceutical company’s existing and pipeline products to healthcare professionals.

Syros Pharmaceuticals today announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, will be featured in a Spotlight poster discussion session at the San Antonio Breast Cancer Symposium taking place December 4-8 in San Antonio.

Nobilis Health Corp. announced today it has filed a Form 12b-25 Notification of Late Filing with the Securities and Exchange Commission (the “SEC”) relating to its 10-Q for the period ended September 30, 2018.

MedEquities Realty Trust, Inc. today announced its consolidated financial results for the quarter ended September 30, 2018 and other recent developments.